Stockholm - Delayed Quote SEK

Mendus AB (publ) (IMMU.ST)

8.20

0.00

(0.00%)

At close: January 10 at 4:52:20 PM GMT+1

Edison Issues Report on Mendus (IMMU)

London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Mendus (OMX: IMMU)Mendus continues to make headway with its lead programme assessing cancer vaccine vididencel as a potential maintenance therapy for acute myeloid leukaemia (AML), with the latest update presented at the 66th annual American Society of Hematology (ASH) meeting in December. Mendus presented encouraging long-term survival data from the ADVANCE II trial investigating vididencel as monotherapy, wh

Newsfile 25 days ago

IMMU.ST
0.00%
Mendus AB (STU:1YG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Mendus AB (STU:1YG0) reports significant progress in clinical trials and manufacturing alliances, despite a Q3 net loss of 23 million.

GuruFocus.com 2 months ago

1YG0.SG
Mendus to present NK cell program progress at the Innate Killer Summit

Press Release Stockholm, Sweden, March 19, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will present the progress of its NK cell program at the 9th Annual Innate Killer Cell Summit, a leading conference for NK cell-based therapies. Mendus Director of Research Satwinder Kaur Singh, PhD will be expert speaker at the 9th Annual Innate Killer Summit held March 18-20 in San Diego, CA, USA. The Innate Kil

GlobeNewswire 9 months ago

IMMU-TO3.ST

IMMU.ST
0.00%
Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3

Press Release Stockholm, Sweden, March 15, 2024 Mendus AB (“Mendus” or the “Company”) has received written declarations of intent whereby the Company’s major shareholders, holding approximately 65.8 percent of shares in the Company, declare their intention to exercise warrants of series TO3 (the “Warrants”) to subscribe for newly issued shares corresponding to their holdings of Warrants during the subscription period 15-29 March 2024 at the subscription price of 0.48 SEK per share. The major sha

GlobeNewswire 9 months ago

IMMU-TO3.ST

IMMU.ST
0.00%
The exercise period for warrants of series TO3 commences today

Press Release Stockholm, Sweden, March 15, 2024 On June 8, 2023, Mendus AB (publ) (“Mendus” or the “Company”), (NASDAQ Stockholm: IMMU), announced that the Board of Directors had resolved on a capital raise of approximately SEK 317 million (the “Transaction”), comprised of a directed issue of shares and warrants to Flerie Invest AB of approximately SEK 90 million (the “Directed Issue”), in combination with a fully secured rights issue of units of approximately SEK 227 million (the “Rights Issue”

GlobeNewswire 9 months ago

IMMU-TO3.ST

IMMU.ST
0.00%
Mendus provides business update and outlook for vididencel program

Press Release Stockholm, Sweden, March 12, 2024 ADVANCE II Phase 2 trial data provide basis for late-stage development of lead product vididencel in acute myeloid leukemiaRegistration trial preparations are ongoing, following positive initial FDA feedback on main questions related to late-stage clinical development and large-scale manufacturingManufacturing alliance with NorthX Biologics on track, with production facility installed and tech transfer process for large-scale GMP manufacturing of v

GlobeNewswire 9 months ago

IMMU-TO3.ST

IMMU.ST
0.00%
Mendus to participate in upcoming industry conferences

Press release Stockholm, Sweden, February 27, 2024 Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming industry conferences: 10th annual IO360° Summit New York, USA, February 27-29, 2024 CEO Erik Manting will participate in the 10th annual IO360° Summit, a conference dedicated to reporting on the latest advancements and data in Immuno-Oncology. https://io360summi

GlobeNewswire 10 months ago

IMMU-TO3.ST

IMMU.ST
0.00%
Mendus to hold Business Update event on March 12

Press Release Stockholm, Sweden, February 23, 2024 Mendus AB (“Mendus” publ; IMMU.ST), will hold an in-person and live-streamed business update event in Stockholm on March 12, 15:00-17:00 CET to discuss the company’s latest pipeline advancements. Mendus has recently presented positive Phase 2 data with vididencel in acute myeloid leukemia (AML), an aggressive blood-borne tumor associated with high relapse rates, at the ASH 2023 conference. Vididencel addresses the need for safe and effective AML

GlobeNewswire 10 months ago

IMMU-TO3.ST

IMMU.ST
0.00%
Mendus AB Year-end Report for 2023

Press Release Stockholm, Sweden, February 14, 2024 Positive ADVANCE II data at ASH caps strong 2023 The fourth quarter of 2023 closes a crucial year for Mendus and delivered additional milestones to further strengthen the development of our lead product vididencel as a novel maintenance treatment for acute myeloid leukemia (AML). Mendus is at an exciting point in its journey, supported by continued positive clinical data confirming the potential of vididencel to significantly improve disease-fre

GlobeNewswire 10 months ago

IMMU-TO3.ST

IMMU.ST
0.00%
Invitation to presentation of Mendus’ year-end report for 2023

Mendus AB (“Mendus” publ; IMMU.ST), will publish its year-end report for 2023 on Wednesday 14 February 2024 at 08:00 CET. The company will hold a conference call and an online presentation on the same day at 10:00 CET. The call will be hosted by CEO Erik Manting. The presentation will be in English and followed by a question-and-answer session. Listen to the presentation webcast: https://ir.financialhearings.com/mendus-q4-2023 Please send any questions ahead of the presentation to ir@mendus.com

GlobeNewswire 10 months ago

IMMU-TO3.ST

IMMU.ST
0.00%

Performance Overview

Return	IMMU.ST	OMX Stockholm 30 Index
YTD	+5.11%	+1.64%
1-Year	-18.81%	+7.63%
3-Year	-87.97%	+5.11%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Mendus AB (publ) (IMMU.ST)

Edison Issues Report on Mendus (IMMU)

Mendus AB (STU:1YG0) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

Mendus to present NK cell program progress at the Innate Killer Summit

Mendus’ major shareholders and members of the Board of Directors and Management declare their intention to exercise warrants of series TO3

The exercise period for warrants of series TO3 commences today

Mendus provides business update and outlook for vididencel program

Mendus to participate in upcoming industry conferences

Mendus to hold Business Update event on March 12

Mendus AB Year-end Report for 2023

Invitation to presentation of Mendus’ year-end report for 2023

Performance Overview